Literature DB >> 21453728

A mixture of bacterial mechanical lysates is more efficient than single strain lysate and of bacterial-derived soluble products for the induction of an activating phenotype in human dendritic cells.

Barbara Morandi1, Alessia Agazzi, Antonella D'Agostino, Francesca Antonini, Gregorio Costa, Federica Sabatini, Guido Ferlazzo, Giovanni Melioli.   

Abstract

Dendritic cells (DCs), following an optimal maturation, are able to drive an efficient immune-response. For this, both co-stimulatory molecules (CD80 and CD86), activation molecules (CD83) and peptide presenting molecules (HLA) are over-expressed. The in vitro treatment of immature DC with fragments of bacterial strains, obtained by using a mechanical lysis as well as with bacterial-derived molecules (such as lipopolysaccharide and protido-glycan), induced the maturation of DCs and the secretion of a panel of cytokines and chemokines. Of note, ex vivo treated circulating DCs and plasmacytoid DCs were also activated by these bacterial bodies. However, while the particulate fraction of single bacterial strains or soluble bacterial-derived molecules induced a sub-optimal maturation (as evaluated by the expression of an activating phenotype on DCs and the amount of cytokine secretion), the addition of the mixture of the particulate fractions of the different bacterial strains was able to mediate an optimal maturation. These results were also confirmed by using the secretion of both cytokines and chemokines as markers of DC activation. All these findings suggest that the particulate fraction of bacterial lysate mixtures, because of their ability to interact with different surface structures, might be exploited not only as an immunogen, but also as an adjuvant treatment to boost an immune-response to poorly "antigenic" proteins, such as cancer antigens or allergens.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21453728     DOI: 10.1016/j.imlet.2011.03.006

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  10 in total

Review 1.  The Shift of an Intestinal "Microbiome" to a "Pathobiome" Governs the Course and Outcome of Sepsis Following Surgical Injury.

Authors:  Monika A Krezalek; Jennifer DeFazio; Olga Zaborina; Alexander Zaborin; John C Alverdy
Journal:  Shock       Date:  2016-05       Impact factor: 3.454

2.  A Case-Control Study on the Changes in Natural Killer Cell Activity following Administration of Polyvalent Mechanical Bacterial Lysate in Korean Adults with Recurrent Respiratory Tract Infection.

Authors:  Yun Kyong Lee; Ji-Hee Haam; Eunkyung Suh; Sung Hoon Cho; Young-Sang Kim
Journal:  J Clin Med       Date:  2022-05-26       Impact factor: 4.964

3.  Protective effect of mitochondria-targeted antioxidants in an acute bacterial infection.

Authors:  Egor Y Plotnikov; Maria A Morosanova; Irina B Pevzner; Ljubava D Zorova; Vasily N Manskikh; Natalya V Pulkova; Svetlana I Galkina; Vladimir P Skulachev; Dmitry B Zorov
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-29       Impact factor: 11.205

4.  Clinical efficacy and tolerability of an immune-stimulant(*) constituted by inactivated bacterial bodies in the prophylaxis of infectious episodes of airways: a double blind, placebo-controlled, randomized, multicentre study.

Authors:  Stefano Carlone; Michele Minenna; Paride Morlino; Luigi Mosca; Franco Pasqua; Riccardo Pela; Pietro Schino; Alberto Tubaldi; Emmanuele Tupputi; Fernando De Benedetto
Journal:  Multidiscip Respir Med       Date:  2014-11-19

Review 5.  Immunostimulants in respiratory diseases: focus on Pidotimod.

Authors:  Francesca Puggioni; Magna Alves-Correia; Manar-Farouk Mohamed; Niccolò Stomeo; Riccardo Mager; Massimiliano Marinoni; Francesca Racca; Giovanni Paoletti; Gilda Varricchi; Veronica Giorgis; Giovanni Melioli; Giorgio Walter Canonica; Enrico Heffler
Journal:  Multidiscip Respir Med       Date:  2019-11-04

6.  The bacterial lysate Lantigen B reduces the number of acute episodes in patients with recurrent infections of the respiratory tract: the results of a double blind, placebo controlled, multicenter clinical trial.

Authors:  Fulvio Braido; Giovanni Melioli; Piero Candoli; Andrea Cavalot; Mario Di Gioacchino; Vittorio Ferrero; Cristoforo Incorvaia; Carlo Mereu; Erminia Ridolo; Giovanni Rolla; Oliviero Rossi; Eleonora Savi; Libero Tubino; Giorgio Reggiardo; Ilaria Baiardini; Eddi di Marco; Gilberto Rinaldi; Giorgio Walter Canonica; Carlo Accorsi; Claudia Bossilino; Laura Bonzano; Michela DiLizia; Barbara Fedrighini; Valentina Garelli; Vincenzo Gerace; Sara Maniscalco; Ilaria Massaro; Alessandro Messi; Manlio Milanese; Silvia Peveri; Arminio Penno; Stefano Pizzimenti; Tiziana Pozzo; Alberto Raie; Sergio Regina; Francesca Sclifò
Journal:  Immunol Lett       Date:  2014-11-03       Impact factor: 3.685

7.  Impact of Polyvalent Mechanical Bacterial Lysate on lymphocyte number and activity in asthmatic children: a randomized controlled trial.

Authors:  Małgorzata Bartkowiak-Emeryk; Andrzej Emeryk; Jacek Roliński; Ewelina Wawryk-Gawda; Ewa Markut-Miotła
Journal:  Allergy Asthma Clin Immunol       Date:  2021-01-20       Impact factor: 3.406

Review 8.  The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics.

Authors:  Seppo Salminen; Maria Carmen Collado; Akihito Endo; Colin Hill; Sarah Lebeer; Eamonn M M Quigley; Mary Ellen Sanders; Raanan Shamir; Jonathan R Swann; Hania Szajewska; Gabriel Vinderola
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-05-04       Impact factor: 73.082

Review 9.  Promising Immunomodulatory Effects of Bacterial Lysates in Allergic Diseases.

Authors:  Agnieszka Kaczynska; Martyna Klosinska; Kamil Janeczek; Michał Zarobkiewicz; Andrzej Emeryk
Journal:  Front Immunol       Date:  2022-06-22       Impact factor: 8.786

10.  Broncho-Vaxom attenuates allergic airway inflammation by restoring GSK3β-related T regulatory cell insufficiency.

Authors:  Ran Fu; Jian Li; Hua Zhong; Dehong Yu; Xianping Zeng; Mengxia Deng; Yueqi Sun; Weiping Wen; Huabin Li
Journal:  PLoS One       Date:  2014-03-25       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.